Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs Inc. is advancing its clinical-stage pipeline with a focus on innovative vaccines and immunotherapies, highlighted by the positive developments in its next-generation COVID-19 vaccine, GEO-CM04S1, which has shown promising Phase 2 results in immunocompromised populations. The company has leveraged favorable regulatory feedback to accelerate its Mpox/Smallpox vaccine development and enhance its collaborations, thereby positioning itself to capitalize on its competitive valuation. Furthermore, Geovax's ongoing initiatives in oncology, alongside the scalable AGE1 avian cell-line manufacturing platform, suggest strong growth potential and strategic alignment with public health needs.

Bears say

The negative outlook on Geovax Labs Inc. is driven by a combination of limited liquidity, a depressed share price, and heightened execution risks due to a challenging financing environment, with just $5 million available at the end of Q3. The company's high cash burn rate amid ongoing research and development activities raises concerns about the likelihood of requiring additional financing in a sector where nearly 40% of public biotechs might deplete their cash reserves within the next year. Furthermore, the increasing caution among biotechnology investors and the reliance on successful clinical trial outcomes intensifies the perceived risks associated with Geovax’s equity, ultimately contributing to the decision to lower the valuation target from $9.00 to $6.00.

Geovax Labs (GOVX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Geovax Labs (GOVX) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.